

Genomic DNA from Vaccinia Virus, Western Reserve (NIAID, Tissue Culture Adapted)

Catalog No. NR-2639

For research use only. Not for use in humans.

Contributor:

ATCC®

Manufacturer:

BEI Resources

Product Description:

Genomic DNA was isolated from a preparation of cell lysate and supernatant from African green monkey cells (Vero; ATCC® CCL-81™) infected with vaccinia virus, Western Reserve (WR; NIAID, tissue culture adapted), which was derived from the original New York City Board of Health (NYCBOH) strain by intracerebral passages in mice followed by tissue culture adaptation.^{1,2} It has been utilized in constructing vectors for gene expression and in producing viral proteins and DNA.^{3,4} The complete genomic sequence of vaccinia virus, WR has been determined (GenBank: [AY243312](https://www.ncbi.nlm.nih.gov/nuccore/AY243312)).⁵

NR-2639 has been qualified for PCR applications by amplification of a sequence of at least 1100 base pairs. See Certificates of Analysis for details. NR-2639 is not intended for use as a standard for quantitative PCR.

Material Provided:

Each vial contains approximately 100 µL of viral genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The viral genomic DNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-2639 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from Vaccinia Virus, Western Reserve (NIAID, Tissue Culture Adapted), NR-2639."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbL5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Parker, R. F., L. H. Bronson and R. H. Green. "Further Studies of the Infectious Unit of Vaccinia." J. Exp. Med. 74 (1941): 263-281.
2. Bronson, L. H. and R. F. Parker. "The Neutralization of Vaccine Virus by Immune Serum: Titration by the Intracerebral Inoculation of Mice." J. Bacteriol. 41 (1941): 56-57.
3. Mackett, M. and G. L. Smith. "Vaccinia Virus Expression Vectors." J. Gen. Virol. 67 (1986): 2067-2082. PubMed: 3531399.
4. Salzman, N. P. and E. D. Sebring. "Sequential Formation of Vaccinia Virus Proteins and Viral Deoxyribonucleic Acid Replication." J. Virol. 1 (1967): 16-23. PubMed: 4248263.
5. Esposito, J. J., et al. "Vaccinia Virus, Complete Genome." Direct submission, 24 Feb 2003. GenBank: AY243312.
6. Smee, D. F., et al. "Characterization and Treatment of Cidofovir-Resistant Vaccinia (WR Strain) Virus Infections in Cell Culture and in Mice." Antivir. Chem. Chemother. 16 (2005): 203-211. PubMed: 16004083.
7. Gallego-Gómez, J. C., et al. "Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA

and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells." J. Virol. 77 (2003): 10606-10622. PubMed: 12970445.

8. Ramirez, J. C., M. M. Gherardi and M. Esteban. "Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine." J. Virol. 74 (2000): 923-933. PubMed: 10623755.

ATCC® is a trademark of the American Type Culture Collection.

